Alia-Klein, N., O’Rourke, T., Goldstein, R., & Malaspina, D. (2007). Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggressive Behavior, 33, 86–96.Google Scholar

Beck, N., Greenfield, S., Gotham, H., Menditto, A., Stuve, P., & Hemme, C. (1997). Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. Journal of the American Academy of Psychiatry and the Law, 25, 461–468.Google Scholar

Bitter, I., Czobor, P., Dossenbach, M., & Volavka, J. (2005). Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). European Psychiatry, 20, 403–408.Google Scholar

Buckley, P., Ibrahim, Z., Singer, B., Orr, B., Donenwirth, K., & Brar, P. (1997). Aggression and schizophrenia: efficacy of risperidone. Journal of the American Academy of Psychiatry and Law, 25, 173–181.Google Scholar

Caspi, N., Modai, I., Barak, P., Waisbourd, A., Zbarsky, H., Hirschmann, S., & Ritsner, M. (2001). Pindolol augmentation in aggressive schizophrenic patients: a double- blind crossover randomized study. International Clinical Psychopharmacology, 97, 111–115.Google Scholar

Citrome, L. (2007). Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Journal of Clinical Psychiatry, 68, 1876–1885.Google Scholar

Citrome, L. (2012). Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. International Journal of Clinical Practice, 66, 318–325.CrossRefGoogle ScholarPubMed

Citrome, L. (2013). Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Therapeutic and Clinical Risk Management, 9, 235–245.Google Scholar

Citrome, L. (2013). New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Reviews in Neurotherapy, 13, 767–783.Google Scholar

Citrome, L., Casey, D., Daniel, D., Wozniak, P., Kochan, L., & Tracy, K. (2004). Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatric Services, 55, 290–294.CrossRefGoogle ScholarPubMed

Citrome, L., Du, Y., Risinger, R., Stankovic, S., Claxton, A., Zummo, , … & Ehrich, W. (2016). Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International Clinical Psychopharmacology, 31, 69–75.Google Scholar

Citrome, L., Holt, R., Walker, D., & Hoffmann, V. (2011). Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clinical Drug Investigation, 31, 455–482.Google Scholar

Citrome, L., Shope, C., Nolan, K., Czobor, P., & Volavka, J. (2007). Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. International Clinical Psychopharmacology, 22, 356–362.Google Scholar

Citrome, L. & Volavka, J. (2014). The psychopharmacology of violence: making sensible decisions. CNS Spectrums, 19, 411–418.Google Scholar

Citrome, L., Volavka, J., Czobor, P., Brook, S., Loebel, A., & Mandel, F. (2006). Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. Journal of Clinical Psychiatry, 67, 638–642.CrossRefGoogle ScholarPubMed

Citrome, L., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J., McEvoy, J., … & Lieberman, J. (2001). Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility in treatment-resistant patients with schizophrenia and schizoaffective disorder. Psychiatric Services, 52, 1510–1514.Google Scholar

Comai, S., Tau, M., Pavlovic, Z., & Gobbi, G. (2012). The Psychopharmacology of Aggressive Behavior: A Translational Approach: Part 2: Clinical Studies Using Atypical Antipsychotics, Anticonvulsants, and Lithium. Journal of Clinical Psychopharmacology, 32, 83–94.Google Scholar

Cullen, A., Clarke, A., Kuipers, E., Hodgins, S., Dean, K., & Fahy, T. (2012). A multisite randomized trial of a cognitive skills program for male mentally disordered offenders: Violence and antisocial behavior outcomes. Psychological Medicine, 42, 557–569.Google Scholar

Czobor, P., Volavka, J., & Meibach, R. (1995). Effect of risperidone on hostility in schizophrenia. Journal of Clinical Psychopharmacology, 15, 243–249.Google Scholar

Eli Lilly and Company. (2015). Zyprexa Prescribing Information. Retrieved June 14, 2016 from pi.lilly.com/us/zyprexa-pi.pdf.Google Scholar

Fazel, S., Gulati, G., Linsell, L., Geddes, J., & Grann, M. (2009). Schizophrenia and violence: systematic review and meta-analysis. PLoS Medicine, 6, e1000120.Google Scholar

Frogley, C., Taylor, D., Dickens, G., & Picchioni, M. (2012). A systematic review of the evidence of clozapine's anti-aggressive effects. International Journal of Neuropsychopharmacol, 15, 1351–1371.Google Scholar

Galen US Inc. (2017). Adasuve Prescribing Information. Retrieved December 6, 2017 from www.adasuve.com/PDF/AdasuvePI.pdf.Google Scholar

Haddock, G., Barrowclough, C., Shaw, J., Dunn, G., Novaco, R., & Tarrier, N. (2009). Cognitive-behavioural therapy v. social activity therapy for people with psychosis and a history of violence: randomised controlled trial. British Journal of Psychiatry, 194, 152–157.CrossRefGoogle Scholar

Huband, N., Ferriter, M., Nathan, R., & Jones, H. (2010). Antiepileptics for aggression and associated impulsivity. Cochrane Database of Systematic Reviews, 2, No. CD003499. doi: 10.1002/14651858.CD003499.pub3.Google Scholar

Kay, S., Opler, L., & Lindenmayer, J. (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry, 155, 59–65.Google Scholar

Kay, S., Wolkenfeld, F., & Murrill, L. (1988). Profiles of aggression among psychiatric patients. I. Nature and prevalence. Journal of Nervous and Mental Disease, 176, 539–546.CrossRefGoogle ScholarPubMed

Knoedler, D. (1989). The Modified Overt Aggression Scale. American Journal of Psychiatry, 146, 1081–1082.Google Scholar

Krakowski, M., Czobor, P., Citrome, L., Bark, N., & Cooper, T. (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry, 63, 622–629.Google Scholar

Lindenmayer, J., Liu-Seifert, H., Kulkarni, P., Kinon, B., Stauffer, V., Edwards, S., … & Volavka, J. (2009). Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. Journal of Clinical Psychiatry, 70, 990–996.Google Scholar

Montoya, A., Valladares, A., Lizan, L., San, L., Escobar, R., & Paz, S. (2011). Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Quality of Life Outcomes, 9, 18.CrossRefGoogle Scholar

Nolan, K., Czobor, P., Roy, B., Platt, M., Shope, C., Citrome, L., & Volavka, J. (2003). Characteristics of assaultive behavior among psychiatric inpatients. Psychiatric Services, 54, 1012–1016.CrossRefGoogle ScholarPubMed

Nordstrom, K., Zun, L., Wilson, M., Ng, A., Bregman, B., & Anderson, E. (2012). Medical evaluation and triage of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project Beta Medical Evaluation Workgroup. West Journal of Emergency Medicine, 13, 3–10.Google Scholar

Otsuka Pharmaceutical Company. (2016). Abilify Prescribing Information. Retrieved June 14, 2016 from www.otsuka-us.com/media/images/AbilifyPI_538.pdf.Google Scholar

Pfizer Inc. (2015). Geodon prescribing information. Retrieved June 14, 2016 from http://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=584.Google Scholar

Pratts, M., Citrome, L., Grant, W., Leso, L., & Opler, L. (2014). A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatrica Scandinavica, 130, 61–68.Google Scholar

Richmond, J. S., Berlin, J. S., Fishkind, A. B., Holloman, G. H., Jr., Zeller, S. L., Wilson, M. P., Rifai, M. A., Ng, A. T. (2012). Verbal De-escalation of the Agitated Patient: Consensus Statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup. The Western Journal of Emergency Medicine, 13, 17–25.Google Scholar

Steadman, E., Mulvey, E., Monahan, J., Robbins, P., Appelbaum, P., Grisso, T., … & Silver, E. (1998). Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Archives of General Psychiatry, 55, 393–401.Google Scholar

Swanson, J., Swartz, M., Van Dorn, R., Elbogen, E., Wagner, H., Rosenheck, R., … & Lieberman, J. (2006). A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry, 63, 490–499.Google Scholar

Swanson, J., Swartz, M., Van Dorn, R., Volavka, J., Monahan, J., Stroup, T., … & Lieberman, J. (2008a). Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. British Journal of Psychiatry, 193, 37–43.Google Scholar

Swanson, J., Van Dorn, R., Swartz, M., Smith, A., Elbogen, E., & Monahan, J. (2008b). Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law & Human Behavior, 32, 228–240.Google Scholar

Swift, R., Harrigan, E., Cappelleri, J., Kramer, D., & Chandler, L. (2002). Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. Journal of Psychiatric Research, 36, 87–95.CrossRefGoogle Scholar

Tiihonen, T., Lonnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). The Lancet, 374, 620–627.Google Scholar

Volavka, J. (2002). Neurobiology of violence. Washington, DC: American Psychiatric Publishing.Google Scholar

Volavka, J. (2014). Comorbid personality disorders and violent behavior in psychotic patients. Psychiatric Quarterly, 85, 65–78.Google Scholar

Volavka, J. & Citrome, L. (2011). Pathways to aggression in schizophrenia affect results of treatment. Schizophrenia Bulletin, 37, 921–929.Google Scholar

Volavka, J., Czobor, P., Citrome, L., & Van Dorn, R. (2014). Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectrums, 19, 374–381.Google Scholar

Volavka, J., Czobor, P., Derks, E., Bitter, I., Libiger, J., Kahn, R., & Fleischhacker, W. (2011). Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). Journal of Clinical Psychiatry, 72, 955–961.Google Scholar

Volavka, J., Czobor, P., Nolan, K., Sheitman, B., Lindenmayer, J., Citrome, L., … & Lieberman, A. (2004). Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. Journal of Clinical Psychopharmacology, 24, 225–228.Google Scholar

Volavka, J., Swanson, J., & Citrome, L. (2012). Understanding and managing violence in Schizophrenia. In Lieberman, J. A. & Murray, R. M. (Eds), Comprehensive Care of Schizophrenia: A Textbook of Clinical Management (pp. 262–290). New York: Oxford University Press.Google Scholar

Volavka, J., Van Dorn, R., Citrome, L., Kahn, R., Fleischhacker, W., & Czobor, P. (2016). Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. European Psychiatry, 31, 13–19.Google Scholar

Whitman, J., Maier, G., & Eichelman, B. (1987). Beta-adrenergic blockers for aggressive behavior in schizophrenia. American Journal of Psychiatry, 144, 538–539.Google Scholar

Wilson, M., Pepper, D., Currier, G., Holloman, Jr., G., & Feifel, D. (2012). The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. Western Journal of Emergency Medicine, 13, 26–34.Google Scholar

Yates, K., Kunz, M., Khan, A., Volavka, J., & Rabinowitz, S. (2010). Psychiatric patients with histories of aggression and crime five years after discharge from a cognitive-behavioral program. Journal of Forensic Psychiatry & Psychology, 21, 167–188.Google Scholar

Yudofsky, S., Silver, J., Jackson, W., Endicott, J., & Williams, D. (1986). The Overt Aggression Scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry, 143, 35–39.Google Scholar

Zedie, N., Amory, D., Wagner, B., & O’Hara, D. (1996). Comparison of intranasal midazolam and sufentanil premedication in pediatric outpatients. Clinical Pharmacology Therapy, 59, 341–348.Google Scholar

Zeller, S. & Citrome, L. (2016). Managing agitation associated with Schizophrenia and Bipolar Disorder in the emergency setting. Western Journal of Emergency Medicine, 17, 165–172.Google Scholar